Obesity Today—March 17, 2026

This week’s Obesity update highlights regulatory approvals, emerging generic competition, manufacturing expansion for oral therapies, access initiatives, and increasing safety oversight.

In this Newsletter

Dive deeper

⚠️ Novo Nordisk gets FDA warning on semaglutide adverse event reporting [1] [US • 10 Mar 2026]

https://www.wsj.com/health/pharma/fda-warns-novo-nordisk-of-unreported-side-effects-tied-to-glp-1-patients-c97d810e
Context: FDA’s March 5 warning letter followed an inspection of Novo Nordisk’s U.S. operations and cited problems in reporting potential adverse events tied to semaglutide products.
Key point: The agency cited unreported or improperly reported cases, including deaths and suicidal ideation reports, but did not conclude the events were caused by Ozempic or Wegovy.
Implication: May influence prescriber choice and payer reviews pending full data.

💉 Ascletis reports positive U.S. Phase II topline for ASC30 depot [2] [US • 10 Mar 2026]

https://www.prnewswire.com/news-releases/ascletis-announces-positive-topline-results-from-us-phase-ii-24-week-study-for-its-ultra-long-acting-subcutaneous-depot-formulations-of-small-molecule-glp-1r-agonist-asc30-for-obesity-302709245.html
Context: In a randomized, double-blind, placebo-controlled U.S. Phase II study, 65 participants received three monthly doses; formulation A1 was the active depot formulation.
Key point: Ascletis said ASC30 depot A1 met the primary endpoint and showed placebo-adjusted weight loss through 24 weeks, supporting once-monthly treatment and potential less-frequent maintenance dosing.
Implication: May influence prescriber choice and payer reviews pending full data.

🏫 WHO Foundation and Novo Nordisk back childhood obesity prevention in India [3] [India • 11 Mar 2026]

https://www.who.foundation/post/who-foundation-and-novo-nordisk-announce-collaboration-to-support-childhood-obesity-prevention-in-india
Context: The program aligns with India’s Ayushman Bharat School Health and Wellness Programme and WHO’s Health Promoting Schools framework.
Key point: The collaboration will support school-based obesity prevention, early risk identification, healthier environments, and primary care readiness in targeted districts in India.
Implication: May expand screening, initiation, and follow-up at scale.

🏭 Eli Lilly commits $3 billion to China and advances orforglipron plans [4] [China • 11 Mar 2026]

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-invest-3-billion-china-over-next-decade-2026-03-11/
Context: Lilly said the investment will build local manufacturing and supply capacity for oral solid dosage forms and support its China footprint over the next decade.
Key point: The company said it filed a marketing application in China for orforglipron in late 2025 and is linking manufacturing expansion to its oral obesity and diabetes pipeline.
Implication: Signals pipeline investment and modality expansion.

🧪 Lilly warns about compounded tirzepatide mixed with vitamin B12 [5] [US • 12 Mar 2026]

https://investor.lilly.com/news-releases/news-release-details/open-letter-eli-lilly-and-company-warning-potential-patient
Context: Lilly said its testing found an impurity formed when tirzepatide was compounded with vitamin B12, and said the effects in humans are unknown.
Key point: The company urged caution around compounded tirzepatide-B12 products, notified FDA, and called for stronger action against unlawful mass compounding.
Implication: Could inform practice and payer discussions, interpretation depends on study design and confounding control.

🚨 South Korea reports Mounjaro shortages as obesity-drug demand rises [6] [South Korea • 13 Mar 2026]

https://www.khan.co.kr/en/article/202603131503057
Context: Korean reporting described shortages of the 5 mg starting step-up dose, with supply strain linked to high weight-loss demand and limited public supply management for non-reimbursed obesity use.
Key point: Patients using tirzepatide for diabetes or obesity reportedly faced difficulty accessing Mounjaro, especially in Seoul, while reimbursement and supply policy debates continued.
Implication: Introduces competition that may affect pricing and formulary access.

🇰🇷 Eli Lilly outlines a $500 million Korea investment and biotech expansion [7] [South Korea • 13 Mar 2026]

https://www.chosun.com/english/industry-en/2026/03/12/MBXAMV4EU5DE3MI2TXMPCL44N4/
Context: Lilly said it signed an MOU with South Korea’s Ministry of Health and Welfare and plans investment over five years starting in 2026.
Key point: The company said it will bring Lilly Gateway Labs to Korea, support local biotech companies, and deepen its Korea presence across obesity, Alzheimer’s, and innovation infrastructure.
Implication: Signals pipeline investment and modality expansion.

🩺 Biomea Fusion shares 52-week Phase II diabetes follow-up for icovamenib [8] [EU • 14 Mar 2026]

https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-presents-phase-ii-covalent-111-data-type-2
Context: At ATTD 2026 in Barcelona, Biomea presented follow-up data from COVALENT-111, a randomized, placebo-controlled Phase II study in type 2 diabetes.
Key point: The company reported durable HbA1c improvements through Week 52 in selected subgroups, including severe insulin-deficient diabetes and patients already on GLP-1-based therapy.
Implication: Could inform practice and payer discussions, interpretation depends on study design and confounding control.

🤝 Samsung Bioepis, EPIS NexLab, and G2GBIO team up on long-acting obesity drugs [9] [South Korea • 16 Mar 2026]

https://biz.chosun.com/en/en-science/2026/03/16/RW5M6BRT45GCJAKY7T73NWTMPM/
Context: Samsung Epis Holdings said Samsung Bioepis and EPIS NexLab signed a joint research and license agreement with G2GBIO and also backed the company with convertible bond investment.
Key point: The deal covers long-acting obesity candidates, including semaglutide-based programs, and uses G2GBIO’s delivery platform to extend dosing intervals.
Implication: Signals pipeline investment and modality expansion.

Why it matters

The week mixed safety-process scrutiny, supply bottlenecks, and manufacturing expansion across the GLP-1 and obesity market.
Oral and long-acting formats remain a central competitive theme, with Lilly, Ascletis, and Samsung-linked groups all emphasizing differentiated dosing models.
Public health and commercial strategies are converging, from childhood obesity prevention in India to local production plans in China and Korea.
Compounding remains a live patient-safety issue, especially where branded demand outpaces supply.
Type 2 diabetes innovation is still broadening beyond incretin-only approaches, with Biomea positioning icovamenib around beta-cell function and phenotype-defined subgroups.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Obesity archive on our research hub page

🎯 Catch up on the Top Obesity news from the past two weeks, curated by the LucidQuest team. 🎬 Watch on YouTube.

FAQ

What did the FDA warning to Novo Nordisk actually say about Ozempic and Wegovy?

It focused on how potential adverse events were reported, not on proving semaglutide caused the cited deaths or suicidal ideation reports. The source also notes the FDA had recently not found a link between GLP-1 drugs and suicide. [1]

Why is Ascletis’ ASC30 result notable versus other obesity programs?

Ascletis is positioning ASC30 as a small-molecule GLP-1 receptor agonist with both oral and depot options. In this readout, the company emphasized once-monthly treatment dosing and possible less-frequent maintenance dosing. [2]

What is Lilly signaling with its China investment around orforglipron?

Lilly is pairing commercial regulatory progress with local manufacturing build-out. That suggests China is a priority market for oral obesity and diabetes products, especially if orforglipron is approved. [4]

Why is Lilly warning specifically about tirzepatide plus vitamin B12?

Lilly said its testing found an impurity created by combining tirzepatide with vitamin B12, and said the clinical effects are unknown. The letter frames this as a patient-safety concern tied to compounded knockoff products. [5]

What is driving the Mounjaro access issue in South Korea?

The report points to strong demand for weight-loss use, supply instability in key dose strengths, and limited government supply management for non-reimbursed obesity prescribing. That combination appears to be affecting access for some diabetes and obesity patients. [6]

What is the Samsung Bioepis and G2GBIO partnership trying to build?

The companies are targeting long-acting obesity medicines, including semaglutide-based candidates, using G2GBIO’s delivery platform to stretch dosing intervals. The agreement also includes strategic investment and rights around additional candidates. [9]

Entities / Keywords

Novo Nordisk (Ozempic, Wegovy, semaglutide)
Ascletis Pharma (ASC30, GLP-1R agonist, depot formulation, ULAP)
WHO Foundation (Health Promoting Schools, Ayushman Bharat School Health and Wellness Programme)
Eli Lilly and Company (orforglipron, tirzepatide, Mounjaro, Zepbound, Lilly Gateway Labs)
Biomea Fusion (icovamenib, COVALENT-111, type 2 diabetes, SIDD)
Samsung Bioepis / EPIS NexLab / Samsung Epis Holdings (long-acting obesity drugs)
G2GBIO (INOLAMP, long-acting delivery platform)
South Korea obesity market (Mounjaro shortage, reimbursement, formulary access)
India childhood obesity prevention (school-based screening, early risk identification)